ALMS โ Alumis Inc ยท catalysts, narrative & risks
Alumis Inc. (NASDAQ: ALMS) โ Research Snapshot (as of 2026-10-04)
Company profile: Alumis is a clinical-stage biopharmaceutical company (formerly Esker Therapeutics) focused on oral, selective allosteric inhibitors of tyrosine kinase 2 (TYK2) for immune-mediated diseases, headquartered in the United States [3], [14]. Its lead candidate is ESK-001 (envudeucitinib), an oral highly selective TYK2 inhibitor being studied in plaque psoriasis, psoriatic arthritis, and systemic lupus erythematosus (SLE); it is also advancing A-005, a CNS-penetrant TYK2 inhibitor [14]. Note that the market-cap figure (~$956.53M) and the Nov 12 earnings date were provided as background and are largely corroborated below by independent sources [4], [15].
Recent Catalysts (last ~1โ3 months)
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ